2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Farnesol: from perfume to Parkinson’s
A ground-breaking Cure Parkinson’s supported study that involved screening over 230,000 molecules has identified farnesol, a commonly found aromatic oil, as a new potential treatment of Parkinson’s.
Is Inhibikase ‘Abl’ to beat nilotinib in treating Parkinson’s?
Inhibikase Therapeutics has designed a novel drug that is similar to the drug nilotinib – previously tested in people with Parkinson’s – but is better at reaching its target in the brain.
New potential drugs for repurposing in Parkinson’s
The development of new drugs is a long and expensive process, taking many years of funding to bring new therapeutics to treat diseases. Drug repurposing offers a means of rapidly testing already available medicines in diseases that they were not originally approved for.
The 2021 International Linked Clinical Trials Meeting
The International Linked Clinical Trials (iLCT) programme is the flagship drug repurposing initiative of Cure Parkinson’s and Van Andel Institute (VAI) focussed on identifying and clinically testing already available drugs that show potential to slow, stop or reverse the progression of Parkinson’s. Every year the iLCT…
Results from the Inosine SURE-PD clinical trial
The results of a large clinical trial, of 300 individuals, of the dietary supplement ‘inosine’ have shown that the treatment had no effect on slowing the progression of Parkinson’s. Inosine elevates levels of urate in the body. Urate is a naturally produced antioxidant that circulates…